罗沙司他对肾性贫血并绝对铁缺乏患者贫血及铁代谢的影响  

Effect of Roxadustat on Anemia and Iron Metabolism in Patients with Renal Anemia and Absolute Iron Deficiency

作　　者：白士先 李素华[1] BAI Shixian;LI Suhua(Yidu Central Hospital of Weifang,Shandong Weifang 262500)

机构地区：[1]潍坊市益都中心医院,山东潍坊262500

出　　处：《深圳中西医结合杂志》2024年第3期86-89,共4页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

基　　金：潍坊市卫生健康委员会科研项目(WFWSJK-2020-185)。

摘　　要：目的:探讨罗沙司他对维持性血液透析并肾性贫血及绝对铁缺乏患者的贫血指标及铁代谢指标的影响。方法:选取2021年1月至2023年1月潍坊市益都中心医院收治的维持性血液透析肾性贫血合并绝对铁缺乏患者的临床资料,筛选出其中符合条件者共60例作为研究对象,按照治疗方法的差异性进行分组,即对照组及观察组,各30例。两组均应用多糖铁复合物,对照组在此基础上应用重组人促红细胞生成素(rhEPO)进行治疗,观察组则应用罗沙司他进行治疗,疗程为3个月。比较两组患者贫血指标、铁代谢指标以及不良反应发生情况。结果:治疗后,两组患者血红蛋白(Hb)水平、红细胞(RBC)计数、红细胞比容(Hct)高于治疗前,差异具有统计学意义(P<0.05);但观察组与对照组比较,差异无统计学意义(P>0.05)。治疗后,两组患者血清铁(SI)、血清铁蛋白(SF)、总铁结合力(TIBC)水平、转铁蛋白饱和度(TSAT)高于治疗前;观察组SI、TIBC水平、TSAT高于对照组,SF水平低于对照组,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论:相较于rhEPO,罗沙司他的治疗效果更为理想,且安全性高,能有效改善患者贫血指标及铁代谢指标。Objective Objective To investigate the effects of roxadustat on anemia index and iron metabolism index in patients with maintenance hemodialysis,renal anemia and absolute iron deficiency.Methods Clinical data of patients with maintenance hemodialysis renal anemia combined with absolute iron deficiency treated in Yidu Central Hospital of Weifang from January 2021 to January 2023 were selected,and a total of 60 eligible patients were selected as research objects,and grouped according to the differences in treatment methods,that is,a control group and an observation group,with 30 cases each.Both groups were treated with polysaccharide iron complex,the control group was treated with recombinant human erythropoietin(rhEPO)on the basis of this treatment,and the observation group was treated with roxadustat,the course of treatment was 3 months.Anemia indexes,iron metabolism indexes and the occurrence of adverse reactions were compared between the two groups.Results After treatment,hemoglobin(Hb)level,red blood cell(RBC)count and hematocrit(Hct)in the two groups were higher than those before treatment,the differences were statistically significant(P<0.05);but there was no significant difference between the observation group and the control group(P>0.05).After treatment,the levels of serum iron(SI),serum ferritin(SF),total iron binding capacity(TIBC)and transferrin saturation(TSAT)in the two groups were higher than those before treatment;The levels of SI,TIBC and TSAT in the observation group were higher than those in the control group,and the SF level was lower than that in the control group,with statistical significance differences(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Compared with rhEPO,roxadustat has more ideal therapeutic effect,high safety,and can effectively improve the anemia indexes and iron metabolism indexes of patients.

关 键 词：肾性贫血 绝对铁缺乏 维持性血液透析 罗沙司他 重组人促红细胞生成素 

分 类 号：R459.5[医药卫生—治疗学] R692[医药卫生—临床医学] R556